Core Viewpoint - The company has approved the repurchase and cancellation of 1,951,260 restricted shares as part of its first phase of the restricted stock incentive plan, which will lead to a reduction in registered capital [1][2]. Group 1 - The company held its annual general meeting on June 26, 2025, where the proposal for the repurchase and cancellation of remaining restricted shares was approved [1]. - The repurchase will be conducted at the lower of the grant price or the market price at the time of repurchase, as stipulated in the incentive plan [1]. - The total number of shares to be repurchased and canceled is 1,951,260, which will affect the company's total share capital [1]. Group 2 - The repurchase and cancellation of shares will result in a decrease in the company's registered capital, and creditors have the right to claim their debts within specified timeframes [2]. - Creditors can submit their claims via mail, fax, or email, and must provide valid proof of their claims [2]. - The company will follow legal procedures for the cancellation of the repurchased shares [2].
国新健康: 关于回购注销部分限制性股票暨通知债权人的公告